TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 178 participants.

Also called NCT02310100

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 178 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02310100
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02310100. Allocation not applicable; no masking; primary purpose treatment. Start 2015-01-21 (actual); primary completion 2017-02 (actual). Results posted on 2019-03-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study
Acronym
TactiCathPAS
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
TactiCath Quartz treatment
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct02310100
Content hash
ffa17cf2fef4c5de8e09e25efc49d2fa109a39bbb63da6e60e954525e5a68b8a